In the single-agent bevacizumab phase II study in patients with advanced HCC, levels of several circulating components including placental growth factor (PGF), VEGF-A, soluble VEGFR-2, and circulating endothelial cells (CECs) were changed (Boige et al., 2012). The gene discussed is PGF; the disease is hepatocellular carcinoma.